Form 483

Oishi Koseido Co., Ltd. Form 483, 2023-09-01

FDA issued a Form 483 to Oishi Koseido Co., Ltd. on 2023-09-01 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

Oishi Koseido Co., Ltd. · Tosu, Japan · Issued September 1, 2023

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

1 Sep 2023
21 CFR 211.100(a)

Changes to Procedures Not Reviewed, Approved

Cited by Teresa I Navas

1 Sep 2023
21 CFR 211.122(a)

Sampling/testing of labeling/packaging materials

Cited by Teresa I Navas

1 Sep 2023
21 CFR 211.166(a)

Lack of written stability program

Cited by Teresa I Navas

1 Sep 2023
21 CFR 211.170(b)

Annual visual exams of drug products

Cited by Teresa I Navas

1 Sep 2023
21 CFR 211.182

Written records kept in individual logs

Cited by Teresa I Navas

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.122(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.170(b)Cited across public-safe Form 483 observations1x
21 CFR 211.182Cited across public-safe Form 483 observations1x
21 CFR 211.68(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 6 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere